Literature DB >> 9376268

Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.

Y Ando1, H Minami, H Saka, M Ando, S Sakai, K Shimokata.   

Abstract

Carboplatin clearance depends on the glomerular filtration rate (GFR), and Calvert's formula is frequently used to achieve a target area under the time vs concentration curve (mg ml(-1) min). Creatinine clearance is a substitute for GFR when creatinine values are determined by the Jaffé method, which is being replaced by the enzymatic method. When the enzymatic method is used, the corresponding creatinine clearance theoretically exceeds GFR, and the use of creatinine clearance as GFR in Calvert's formula results, accordingly, in overdosing of carboplatin. In this study, we have established a model for adjusting the creatinine clearance to offset this bias based on a relationship between creatinine values measured by the Jaffé method and by the enzymatic method: adjusted creatinine clearance (ml min(-1)) = creatinine clearance (ml min(-1)) x [serum creatinine (mg dl(-1))]/[serum creatinine (mg dl(-1)) + 0.2]. Subsequently, we validated this model using the data from 35 lung cancer patients. Estimated clearances of carboplatin with the original equation [creatinine clearance + 25] were systematically higher than observed clearances [mean prediction error (MPE) +/- standard error (s.e.) = 26 +/- 5%]. This positive bias was corrected by the adjustment (MPE +/- s.e. = 5 +/- 4%). When the enzymatic method is used, the adjusted creatinine clearance should be used in Calvert's formula.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376268      PMCID: PMC2228094          DOI: 10.1038/bjc.1997.509

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  A clinical appraisal of the plasma concentration and endogenous clearance of creatinine.

Authors:  P D DOOLAN; E L ALPEN; G B THEIL
Journal:  Am J Med       Date:  1962-01       Impact factor: 4.965

2.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

Authors:  A F LeRoy; M L Wehling; H L Sponseller; W S Friauf; R E Solomon; R L Dedrick; C L Litterst; T E Gram; A M Guarino; D A Becker
Journal:  Biochem Med       Date:  1977-10

Review 3.  Clinical evaluation of kidney function--glomerular function.

Authors:  J P Kassirer
Journal:  N Engl J Med       Date:  1971-08-12       Impact factor: 91.245

4.  Creatinine assay by a reaction-kinetic principle.

Authors:  K Larsen
Journal:  Clin Chim Acta       Date:  1972-10       Impact factor: 3.786

5.  Simple, rapid, kinetic method for serum creatinine measurement.

Authors:  J A Lustgarten; R E Wenk
Journal:  Clin Chem       Date:  1972-11       Impact factor: 8.327

6.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

7.  Limitations of creatinine as a filtration marker in glomerulopathic patients.

Authors:  O Shemesh; H Golbetz; J P Kriss; B D Myers
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

8.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

9.  Multicentre evaluation of an enzymatic method for creatinine determination using a sensitive colour reagent.

Authors:  W G Guder; G E Hoffmann; A Hubbuch; W A Poppe; J Siedel; C P Price
Journal:  J Clin Chem Clin Biochem       Date:  1986-11

10.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more
  17 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

3.  Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.

Authors:  Takuya Koie; Chikara Ohyama; Yasuhiro Hashimoto; Shingo Hatakeyama; Hayato Yamamoto; Takahiro Yoneyama; Noritaka Kamimura
Journal:  Int J Clin Oncol       Date:  2012-07-19       Impact factor: 3.402

4.  Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects.

Authors:  Shiori Nagano; Maasa Takahashi; Nobuyuki Miyai; Mayumi Oka; Miyoko Utsumi; Mitsuru Shiba; Kanae Mure; Tatsuya Takeshita; Mikio Arita
Journal:  Hypertens Res       Date:  2017-02-16       Impact factor: 3.872

5.  Estimation of glomerular filtration rate in cancer patients.

Authors:  J G Wright; A V Boddy; M Highley; J Fenwick; A McGill; A H Calvert
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

Review 6.  Carboplatin dosing for adult Japanese patients.

Authors:  Yuichi Ando; Tomoya Shimokata; Yoshinari Yasuda; Yoshinori Hasegawa
Journal:  Nagoya J Med Sci       Date:  2014-02       Impact factor: 1.131

7.  Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.

Authors:  Seigo Minami; Yoshitaka Ogata; Shouichi Ihara; Suguru Yamamoto; Kiyoshi Komuta
Journal:  World J Oncol       Date:  2017-12-28

8.  Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

9.  Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.

Authors:  Yohei Funakoshi; Yutaka Fujiwara; Naomi Kiyota; Toru Mukohara; Takanobu Shimada; Masanori Toyoda; Yoshinori Imamura; Naoko Chayahara; Hideo Tomioka; Michio Umezu; Naoki Otsuki; Ken-ichi Nibu; Hironobu Minami
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-20       Impact factor: 3.333

10.  Effect of renal function on pemetrexed-induced haematotoxicity.

Authors:  Yosuke Ando; Takahiro Hayashi; Moeko Ujita; Sumie Murai; Hideki Ohta; Kaori Ito; Teppei Yamaguchi; Minori Funatsu; Yoshiaki Ikeda; Kazuyoshi Imaizumi; Kenji Kawada; Kimio Yasuda; Shigeki Yamada
Journal:  Cancer Chemother Pharmacol       Date:  2016-06-10       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.